6篇
您的检索式：作者名="Winblad B."
|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Revised NIA-AA criteria for the diagnosis of Alzheimer’s disease: a step forward but not yet ready for widespread clinical use显示文摘 | Giovanni B. Frisoni Bengt Winblad John T. O’Brien | 2011 | International Psychogeriatrics2011，，8： | 2 |
| 2 | Clinical trials and late‐stage drug development for A lzheimer’s disease: an appraisal from 1984 to 2014显示文摘 | L. S. Schneider F. Mangialasche N. Andreasen H. Feldman E. Giacobini R. Jones V. Mantua P. Mecocci L. Pani B. Winblad M. Kivipelto | 2014 | J Intern Med2014，，： | 2 |
| 3 | 多奈哌齐治疗重度阿尔茨海默病患者:双盲、平行分组、安慰剂对照研究显示文摘Background: The cholinesterase inhibitor donepezil is used to treat mild-to-moderate Alzheimer’s disease. Its efficacy in severe dementia has not been assessed and is controversial. Our aim was to ascertain the effectiveness of donepezil in patients with severe Alzheimer’s disease, by focusing primarily on cognition and activities of daily living. Methods: We did a 6-month, double-blind, parallel-group, placebo-controlled study in 248 patients with severe Alzheimer‘s disease (mini mental state examination score 1-10) who were living in assisted care nursing homes ran by trained staff in Sweden. We assigned patients oral donepezil (5 mg per day for 30 days then up to 10 mg per day thereafter, n=128) or matched placebo (n=120). Our primary endpoints were change from baseline to month 6 in the severe impairment battery (SIB) and modified Alzheimer’s Disease Cooperative Study activities of daily living inventory for severe Alzheimer’s disease (ADCS-ADL-severe). We analysed outcomes for patients with data at baseline and at one or more other timepoints (modified intent-to-treat population) with last observation carried forward used to replace missing data. Findings: 95 patients assigned donepezil and 99 patients assigned placebo completed the study. Patients treated with donepezil improved more in SIB scores and declined less in ADCS-ADL-severe scores at 6 months after initiation of treatment compared with baseline than did controls (least squares [LS] mean difference, 5.7, 95%CI 1.5-9.8; p=0.008, and 1.7, 0.2-3.2; p=0.03, respectively). The incidence of adverse events was comparable between groups (donepezil 82%[n=105] vs placebo 76%[n=91]), with most being transient and mild or moderate in severity. More patients discontinued treatment because of adverse events in the donepezil group (n=20) than in the placebo group (n=8). Interpretation: Donepezil improves cognition and preserves function in individuals with severe Alzheimer’s disease who live in nursing homes. | Winblad B. Kilander L. Eriksson S. 周永(译) | 2006 | 世界核心医学期刊文摘(神经病学分册)2006，2，9： | 2 |
| 4 | Histopathological criteria for progressive dementia disorders: clinical-pathological correlation and classification by multivariate data analysis显示文摘 | I. Alafuzoff K. Iqbal H. Friden R. Adolfsson B. Winblad | 1987 | Acta Neuropathologica1987，，3： | 1 |
| 5 | Uncontrolled diabetes increases the risk of Alzheimer’s disease: a population-based cohort study显示文摘 | W. L. Xu E. Strauss C. X. Qiu B. Winblad L. Fratiglioni | 2009 | Diabetologia2009，，6： | 1 |
| 6 | Sensitivity, specificity, and stability of CSF-tau in AD in a community-based patient sample显示文摘 | N. Andreasen L. Minthon A. Clarberg P. Davidsson J. Gottfries E. Vanmechelen H. Vanderstichele B. Winblad K. Blennow | 1999 | Neurology1999，，7： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员